19 September 2024 : Clinical Research
Intravenous Lidocaine Response as a Predictor for Oral Oxcarbazepine Efficacy in Neuropathic Pain Syndrome: A Prospective Cohort Study
Sukunya Jirachaipitak1ABCDEF, Pramote Euasobhon1ABCDEFG*, Suthanee Cenpakdee1ABEF, Suratsawadee Wangnamthip1ABDE, Pranee Rushatamukayanunt1ABDEDOI: 10.12659/MSM.945612
Med Sci Monit 2024; 30:e945612
Table 1 Demographic data. The data are presented as mean±standard deviation, number (%), or median (min–max).
Characteristics | N=32 |
---|---|
Sex | |
Male | 21 (65.6) |
Female | 11 (34.4) |
Age (year) | 43.6±14.8 |
Body mass index (kg/m) | 22.5±4.2 |
Initial NRS | 7 (4–10) |
DN4 | 7 (0–10) |
Maximal effective dose of oxcarbazepine (mg) | 1800 (600–1800) |
Peripheral nerve injury | 20 (62.5) |
Radicular pain | 3 (9.4) |
Spinal cord injury | 3 (9.4) |
Postherpetic neuralgia | 2 (6.3) |
Phantom limb pain | 2 (6.3) |
Postsurgical pain syndrome | 1 (3.1) |
Trigeminal neuralgia | 1 (3.1) |
Upper extremities | 19 (59.4) |
Lower extremities | 6 (18.8) |
Head | 3 (9.4) |
Upper body | 2 (6.3) |
Lower body | 2 (6.3) |
NRS – numeric resting scale 0–10; DN-4 – Douleur Neuropathique 4 questionnaire. |